ONCODESIGN PM
Research ONCODESIGN PM (ALOPM.PA) on Bullrun: market cap EUR 6.29M, P/E 1.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALOPM.PA
- ExchangeALXP
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 6.29M
- P/E1.1
- Financial periodFY2025
- RevenueEUR 261.15K
- Revenue growth26.1%
- Net incomeEUR 5.48M
- Gross margin3726.1%
Valuation Snapshot
latest market cap is EUR 6.29M; P/E is 1.1.
Peer valuation comparison
Latest P/E is 1.1x versus a Healthcare sector median of 21.8x (95.0% below).
Latest P/E is 1.1x versus a France median of 14.02x (92.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 261.15K | EUR 5.48M | n/a | 3726.1% | 0.3 | EUR 312.48K | EUR 6.36M | EUR 52.88M |
| FY2024 | EUR 207.04K | -EUR 7.21M | n/a | -3039.8% | -0.4 | EUR 436.92K | EUR 7.58M | -EUR 429.39K |
| FY2023 | EUR 1.07M | -EUR 8.09M | n/a | -615.4% | -0.49 | EUR 322.58K | EUR 8.83M | EUR 3.69M |
| FY2022 | EUR 7.98M | -EUR 231.18K | n/a | 5.8% | -0.01 | EUR 13.37M | EUR 2.60M | EUR 11.78M |
| FY2021 | n/a | n/a | n/a | n/a | -0.43 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | EUR 6.29M | 1.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ONCODESIGN PM
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ONCODESIGN PM's market cap?
ONCODESIGN PM's market capitalization is EUR 6.29M.
What is ONCODESIGN PM's P/E ratio?
ONCODESIGN PM's price-to-earnings (P/E) ratio is 1.1.
What does ONCODESIGN PM do?
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers.